UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000043238
Receipt number R000049270
Scientific Title KOFU study A cross-sectional web survey study on biologics benefit in view of severe asthma patients
Date of disclosure of the study information 2021/02/03
Last modified on 2021/08/05 14:30:28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

KOFU study
A cross-sectional web survey study on biologics benefit in view of severe asthma patients

Acronym

KOFU study
A cross-sectional web survey study on biologics benefit in view of severe asthma patients

Scientific Title

KOFU study
A cross-sectional web survey study on biologics benefit in view of severe asthma patients

Scientific Title:Acronym

KOFU study
A cross-sectional web survey study on biologics benefit in view of severe asthma patients

Region

Japan


Condition

Condition

asthma

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To investigate patients satisfaction, subjective impression, and patients impression for current treatment in severe asthma patients with biologics (BIO) treatment, and those without BIO treatment and previously recommended to use BIO treatment

Basic objectives2

Others

Basic objectives -Others

To investigate explanation process, patients thought, acceptance and refusal of BIO treatment , background of BIO discontinuation, and communication with primary doctor and recognition of severity

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

To evaluate patients satisfaction, subjective impression for asthma and patients impression for current treatment in severe asthma patients with biologics (BIO) treatment, and severe asthma patients without BIO treatment and previously recommended to use BIO treatment

Key secondary outcomes



Base

Study type

Others,meta-analysis etc


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1) Electric informed consent on the web-site
2) Females and males aged 20 years or older at time of enrollment
3) History of physician-diagnosed asthma requiring treatment at one year or more prior to enrolment
4) Be continuously treated by daily ICS or ICS/LABA to enrolment
5) Severe asthma patients treated by high dose ICS plus additional treatment, OCS or biologics

Key exclusion criteria

1) Patients who cannot complete all questions of this survey's questionnaire
2) Patients who answered questions in less than 2 seconds per question in average

Target sample size

700


Research contact person

Name of lead principal investigator

1st name Satoko
Middle name
Last name Sugaya

Organization

AstraZeneca K.K.

Division name

Medical

Zip code

1000005

Address

9F Marunouchi Trust Tower Main Building, 1-8-3 Marunouchi, Chiyoda-ku, Tokyo

TEL

03-6268-2600

Email

satoko.sugaya@astrazeneca.com


Public contact

Name of contact person

1st name Kensuke
Middle name
Last name Fujimoto

Organization

Mebix, Inc.

Division name

Devision of research promotion

Zip code

1050001

Address

10F Toranomon 33 Mori Building, 3-8-21 Toranomon, Minato-ku, Tokyo

TEL

03-4362-4500

Homepage URL


Email

fujimoto@mebix.co.jp


Sponsor or person

Institute

AstraZeneca K.K.

Institute

Department

Personal name



Funding Source

Organization

AstraZeneca K.K.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Institutional Review Board of Takahashi Clinic

Address

5-1-31 Iwayakita-machi, Nada-ku, Kobe-shi, Hyogo

Tel

078-882-6432

Email

kishimoto.satoshi@neues.co.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2021 Year 02 Month 03 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 01 Month 12 Day

Date of IRB

2021 Year 01 Month 21 Day

Anticipated trial start date

2021 Year 02 Month 01 Day

Last follow-up date

2021 Year 04 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

None


Management information

Registered date

2021 Year 02 Month 03 Day

Last modified on

2021 Year 08 Month 05 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000049270


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name